Clever Leaves Holdings (CLVR) AI Stock Analysis

• Market Cap: $351.00
• Dividend Yield: N/A
• Average Volume (3M): 670.00
• Price to Earnings (P/E): ―
• Beta (1Y): 160001.64
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 296
• Sector: Healthcare
• Sector Strength: 76
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -9.73
• Shares Outstanding: 1,754,795
• 10 Day Avg. Volume: 301
• 30 Day Avg. Volume: 670
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.23
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Clever Leaves Holdings faces substantial financial performance challenges, primarily due to ongoing net losses and cash flow issues despite some improvements in gross margins. The strong balance sheet offers some stability, but technical analysis and valuation scores are limited by lack of data and negative profitability. Earnings call insights are neutral, providing little additional impact.

Clever Leaves Holdings Business Overview & Revenue Model

Company Description

Clever Leaves Holdings Inc. (CLVR) is a multinational cannabis company engaged in the cultivation, extraction, manufacturing, and distribution of pharmaceutical-grade cannabinoids. Operating primarily in Latin America and North America, Clever Leaves focuses on the production of high-quality cannabis extracts and finished products, leveraging its large-scale cultivation facilities in Colombia and Portugal. The company is committed to advancing the medical cannabis industry through its innovative practices and adherence to stringent compliance standards.

How the Company Makes Money

Clever Leaves Holdings generates revenue through its diversified business model, which includes the sale of cannabis extracts, such as CBD and THC oils, as well as dried flower and finished goods to pharmaceutical companies, consumer brands, and other enterprises in the cannabis sector. The company capitalizes on its cost-effective production capabilities in Colombia and Portugal to offer competitive prices. Additionally, Clever Leaves engages in strategic partnerships and supply agreements with global entities to expand its market reach and enhance its product distribution. Revenue is further bolstered through its contract manufacturing services, where it offers expertise in formulating and producing cannabis-based products for third-party brands.

Clever Leaves Holdings Financial Statement Overview

Summary

Clever Leaves Holdings shows improved gross profit margins and reduced negative cash flow, but struggles with persistent net losses and negative cash flow. The balance sheet is strong with low leverage, but operational efficiencies need improvement to reach profitability.

Income Statement

The company has shown a declining revenue trend from $17.8M in 2022 to $17.4M in 2023. The gross profit margin improved from 24.3% in 2022 to 37.6% in 2023, indicating better cost management. However, the company faces significant challenges with negative net profit and EBIT margins, reflecting ongoing profitability struggles.

Balance Sheet

Clever Leaves Holdings has a low debt-to-equity ratio of 0.09, suggesting low financial leverage. However, the return on equity is negative due to net losses, implying a need for improved operational efficiency. The equity ratio of 77.5% in 2023 indicates a strong capital structure with substantial equity backing.

Cash Flow

The company experienced a significant reduction in negative free cash flow from -$30.37M in 2022 to -$11.54M in 2023. Despite this improvement, the negative operating cash flow to net income ratio highlights ongoing cash generation issues.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
17.42M	17.80M	15.37M	12.12M	7.83M
	Gross Profit
6.56M	4.33M	6.81M	7.41M	3.10M
	EBIT
-15.59M	-29.16M	-38.70M	-26.85M	-36.54M
	EBITDA
-16.84M	-35.80M	-35.19M	-23.26M	-41.72M
	Net Income Common Stockholders
-17.90M	-66.10M	-45.63M	-41.41M	-48.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.83M	12.45M	37.23M	79.46M	12.04M
	Total Assets
31.24M	52.10M	116.16M	165.88M	95.72M
	Total Debt
2.09M	3.86M	25.09M	33.84M	33.73M
	Net Debt
-4.74M	-8.59M	-12.13M	-45.62M	21.68M
	Total Liabilities
7.03M	11.69M	43.39M	51.57M	45.52M
	Stockholders Equity
24.22M	40.41M	72.77M	114.31M	45.50M
Cash Flow		Free Cash Flow
-11.54M	-30.37M	-43.51M	-25.63M	-55.73M
	Operating Cash Flow
-11.51M	-29.07M	-36.23M	-21.96M	-37.05M
	Investing Cash Flow
4.69M	1.19M	-7.28M	-3.67M	-33.90M
	Financing Cash Flow
656.00K	3.29M	1.83M	91.84M	62.83M

Clever Leaves Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	68 Neutral	$929.55M	16.37	3.80%	―	35.87%	―
SNDL	59 Neutral	$365.37M	―	-8.00%	―	-2.89%	47.06%
Sector *	48 Neutral	$6.36B	1.09	-49.92%	2.63%	17.17%	0.95%
ACB	47 Neutral	$314.49M	24.65	4.78%	―	16.39%	-98.10%
CLVR	46 Neutral	$351.00	―	-73.91%	―	―	―
TLRY	44 Neutral	$555.28M	―	-7.28%	―	18.38%	86.59%
WEED	42 Neutral	$235.42M	―	-84.50%	―	-16.27%	76.17%